We Give Shareholders a Voice
You are hereby notified that Levi & Korsinsky, LLP has commenced an investigation into the fairness of the sale of Genomic Health, Inc. (“Genomic Health” or the “Company”) (NASDAQGS: GHDX) to Exact Sciences Corp. (“Exact Sciences”)(NASDAQCM: EXAS). Under the terms of the deal, Genomic Health stockholders will receive $27.50 in cash and $44.50 in shares of Exact Sciences stock (subject to a 10% collar centered on Exact Sciences’ volume-weighted average price for the 45 trading days ended July 26, 2019) for each share of Genomic Health common stock they own.
The Genomic Health merger investigation concerns whether the Board of Genomic Health breached their fiduciary duties to stockholders by failing to adequately shop the Company before agreeing to enter into this transaction, and whether Exact Sciences is underpaying for Genomic Health shares, thus unlawfully harming Genomic Health shareholders.
To receive more information, please fill out the form.